ultra-low-frequency
(2)
Presidio Medical, Inc.
Presidio Medical is a clinical-stage medical device company in San Mateo, California, developing a proprietary Ultra Low Frequency (ULF) neuromodulation platform. By delivering very low frequency biphasic electrical currents through leads implanted in the epidural space, Presidio's spinal cord stimulation system reversibly blocks the conduction of pain signals along nerves without damaging tissue. Its first target is chronic nociceptive low back pain, a large and underserved indication with no approved SCS therapy. Backed by Deerfield Management and others, the company raised a $72M Series C in 2023 and received FDA IDE approval in 2025 to run its global pivotal FULFILL trial.
Michael Onuscheck
Michael Onuscheck is CEO and Chairman of Presidio Medical, a San Mateo clinical-stage neuromodulation company developing an ultra-low-frequency waveform platform aimed at chronic pain. He joined in September 2021 after two years on the board, returning to neuromodulation after leading Alcon's global businesses and, earlier, Boston Scientific's Neuromodulation division.